DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Finerenone
Finerenone
Optumrx Brand Pipeline Forecast
Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
The Use of a Novel Non-Steroidal Mineralocorticoid Receptor
(CHMP) Agenda for the Meeting on 22-25 March 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Stembook 2018.Pdf
Benefit of Mineralocorticoid Receptor Antagonism In
Peerview.Com/CWT900 Improving Outcomes and Preventing Chronic
Hypertension 2016 Scientific Sessions Abstracts
Product Data Sheet
The RALES Legacy and Finerenone Use on CKD Patients
Comparative Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Heart Failure: a Network Meta-Analysis of Randomized Controlled Trials
The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights
OIIS Publicaciones 2017.Xlsx
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
New Drug Evaluation Monograph Template
CURRENT OPINION Nonsteroidal Antagonists of the Mineralocorticoid Receptor
Top View
The Role of Spironolactone in Patients With
Kerendia (Finerenone)
Kerendia™ (Finerenone) – New Drug Approval Egfr
Mineralocorticoid Receptor
Bioactive Compound Library Plus (96-Well)
Drug Repurposing Compound Library Plus (96-Well)
Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy And/Or Cost Or Just a Men’Sissue?
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Heart Failure: Finerenone Vs Eplerenone for Patients with Hfref
Finerenone) Tablets, for Oral Use Initial U.S
A Randomized Controlled Study of Finerenone Vs. Eplerenone in Patients with Worsening Chronic Heart Failure and Diabetes Mellitu
Abbreviation: Y = Yes, FDA = FDA Approved, EU GMP = EDQM Approved
Chapter 7 1 Finerenone: Third Generation Mineralocorticoid Receptor Antagonist 2 for the Treatment of Heart Failure and Diabetic Kidney Disease 3
Mineralocorticoid Receptor Antagonists: Achieving Cardiovascular Benefit with Minimized Renal Side Effects? European Heart Journal 34 2426–2428
Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes